Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis

被引:139
作者
Ajose, Olawale [2 ]
Mookerjee, Siddharth [3 ]
Mills, Edward J. [4 ]
Boulle, Andrew
Ford, Nathan [1 ,5 ]
机构
[1] Med Sans Frontieres, CH-1211 Geneva, Switzerland
[2] Clinton Hlth Access Initiat, Dar Es Salaam, Tanzania
[3] Univ London Imperial Coll Sci Technol & Med, Natl Ctr Infect Prevent & Management, London, England
[4] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada
[5] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa
关键词
protease inhibitors; second-line failure; viraemia; virological suppression; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; ROLL-OUT; HIV; MORTALITY; EFFICACY; FAILURE; PROGRAM; COST; LOPINAVIR/RITONAVIR;
D O I
10.1097/QAD.0b013e328351f5b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Methods: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Conclusion: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 938
页数:10
相关论文
共 53 条
  • [1] Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa
    Abouyannis, Michael
    Menten, Joris
    Kiragga, Agnes
    Lynen, Lutgarde
    Robertson, Gavin
    Castelnuovo, Barbara
    Manabe, Yukari C.
    Reynolds, Steven J.
    Roberts, Lesley
    [J]. AIDS, 2011, 25 (13) : 1627 - 1635
  • [2] [Anonymous], HIV AIDS DIAGNOSTIC
  • [3] [Anonymous], 2010, CLIN GUID MAN HIV AI
  • [4] Avalos AGT, 2008, 15 C RETR OPP INF BO
  • [5] Bartlett J, 2011, 18 CROI 27 FEBR 2 MA
  • [6] Changes in the risk of death after HIV seroconversion compared with mortality in the general population
    Bhaskaran, Krishnan
    Hamouda, Osamah
    Sannes, Mette
    Boufassa, Faroudy
    Johnson, Anne M.
    Lambert, Paul C.
    Porter, Kholoud
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (01): : 51 - 59
  • [7] Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa
    Boulle, Andrew
    Van Cutsem, Gilles
    Hilderbrand, Katherine
    Cragg, Carol
    Abrahams, Musaed
    Mathee, Shaheed
    Ford, Nathan
    Knight, Louise
    Osler, Meg
    Myers, Jonny
    Goemaere, Eric
    Coetzee, David
    Maartens, Gary
    [J]. AIDS, 2010, 24 (04) : 563 - U1
  • [8] Antiretroviral roll-out: the problem of second-line therapy
    Boyd, Mark
    Emery, Sean
    Cooper, David A.
    [J]. LANCET, 2009, 374 (9685) : 185 - 186
  • [9] Bunupuradah T, 2009, ANTIVIR THER, V14, P241
  • [10] Castelnuovo Barbara, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P52, DOI 10.1177/1545109708328538